HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Methohexital Sodium

HCID 23690443
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
309-36-4
Standard SMILES
C=CCC1(C(C)C#CCC)C(=O)N=C([O-])N(C)C1=O.[Na+]
InChIKey
KDXZREBVGAGZHS-UHFFFAOYSA-M
Molecular formula
C14H17N2NaO3
Average molar mass
284.29 g/mol
Monoisotopic mass
284.11368669

Overview

Sodium methohexital is a white powder. (NTP, 1992)

Names & identifiers

Preferred name
Methohexital Sodium
IUPAC
sodium 5-hex-3-yn-2-yl-1-methyl-4,6-dioxo-5-prop-2-enylpyrimidin-2-olate
English name
methohexital sodium
Molecular formula
C14H18N2O3.Na
Molecular weight
285.29

Names & synonyms

Methohexital sodiumSODIUM METHOHEXITALBrevital309-36-4Brietal sodiumMethohexitone sodiumBrevimytalBrevital SodiumEnallynymal sodiumSodium methohexitoneMethohexital sodium saltMethohexital sodium (USP)
Show more names
Lilly 22451Brevimytal.SODIUMMETHOHEXITALMETHOHEXITAL SODIUMQ: What is METHOHEXITAL SODIUM Q: What is the CAS Number of METHOHEXITAL SODIUM2,4,6(1H,3H,5H)-Pyrimidinetrione,1-methyl-5-(1-methyl-2-pentyn-1-yl)-5-(2-propen-1-yl)-, sodium salt (1:1)
Methohexital sodium [USP]CHEBI:6834Sodium 5-allyl-1-methyl-5-(1-methyl-2-pentynyl)barbiturateDTXSID602603660200PNZ7QBarbituric acid, 5-allyl-1-methyl-5-(1-methyl-2-pentynyl)-, sodium deriv.Barbituric acid, 5-allyl-1-methyl-5-(1-methyl-2-pentynyl)-, sodium saltBrietal sod

Database identifiers

CAS
309-36-4
PubChem CID
23690443
DTXSID
DTXSID6026036

Properties

Computed structural properties

Topological polar surface area
72.8 Ų
Hydrogen bond donors
0
Hydrogen bond acceptors
3
Rotatable bonds
3
Heavy atoms
20
Formal charge
0
Complexity
515

Experimental & physicochemical properties

Solubilitygreater than or equal to 100 mg/mL at 66 °F (NTP, 1992)
Human Drugs · 2 items

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point140 to 147 °F (NTP, 1992)
Physical DescriptionSodium methohexital is a white powder. (NTP, 1992)

Physicochemical properties

CAS DataBase Reference
309 · 309-36-4
FDA UNII
60200 PNZ7Q · 60200PNZ7Q
EPA Substance Registry System
Methohexital sodium (309-36-4)
RIDADR
3249 · 3249
HazardClass
6.1 · 6.1(b)
PackingGroup
III

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Hazard information

DOT LabelPoison
Fire HazardsFlash point data are not available for this chemical, but it is probably combustible. (NTP, 1992)
Health Hazards · 1 item

SYMPTOMS: Allergic reactions to this chemical are manifested by redness and itching of the skin, shortness of breath, anxiety, abdominal pain, restlessness and peripheral vascular collapse. Other toxic reactions include nausea, vomiting, salivation, delirium, circulatory depression, thrombophlebitis, respiratory depression(including apnea), laryngospasm, bronchospasm and hiccups.

Reactive GroupAmides and Imides
Reactivity ProfileSolutions of this material are incompatible with silicone and acid. (NTP, 1992).
Air and Water ReactionsWater soluble.

Safety & protection

Fire FightingFires involving this compound should be controlled with a dry chemical, carbon dioxide or Halon extinguisher. (NTP, 1992)
First Aid · 1 item

EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.

Nonfire Spill Response · 1 item

Chemistry & industry

Pharmacology

Metabolism/Metabolites · 1 item

Metabolism occurs in the liver through demethylation and oxidation. Side-chain oxidation is the most important biotransformation involved in termination of biologic activity. Route of Elimination: Excretion occurs via the kidneys through glomerular filtration. Half Life: 5.6 ± 2.7 minutes

FDA Pharmacological Classification · 2 items

METHOHEXITAL SODIUM

Barbiturate [EPC]; Barbiturates [CS]

MeSH Pharmacological Classification · 1 item

Ultrashort-acting anesthetics that are used for induction. Loss of consciousness is rapid and induction is pleasant, but there is no muscle relaxation and reflexes frequently are not reduced adequately. Repeated administration results in accumulation and prolongs the recovery time. Since these agents have little if any analgesic activity, they are seldom used alone except in brief minor procedures. (From AMA Drug Evaluations Annual, 1994, p174)

Uses & manufacturing

UsesMethohexital is indicated for use as an intravenous anaesthetic. It has also been commonly used to induce deep sedation. It is only used in hospital or similar settings, under strict supervision.
Applications · 4 items

DescriptionMethohexital sodium, sodium 5-allyl-1-methyl-5-(1-methyl-2-pentynyl)- barbiturate, The free acid forms colorless crystals, mp 6 0 – 6 4C. It is prepared by condensing diethyl allyl(1-methyl-2-pentynyl)malonate with N-methylurea .

UsesAmobarbital is used as anesthetics for perioperative sedation as well as in the short-term treatment of insomnia, anxiety, psychosis, control of seizures, and alcohol withdrawal. These agents are also exploited in abuse settings. Abuse of barbiturates started in the 1940s as they were liberally given to military personnel stationed in the South Pacific in order to help them cope with harsh conditions. They were called ‘goofballs’ in this context. After World War II, many servicemen needed detoxification and treatment for barbiturate dependence upon returning to the United States. Reported barbiturate abuse peaked in the 1970s, but has since declined with the increased use of other sedatives such as benzodiazepines. Use of certain long-acting barbiturates as anticonvulsants, however, continues. Phenobarbital is currently the most commonly prescribed anticonvulsant in use worldwide. Pentobarbital has been used in the United States for lethal injection during executions. Phenobarbital is also used for the treatment of alcohol withdrawal and compares favorably to other agents including benzodiazepines.

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
ChEMBL
CHEMBL30219
ChEBI
CHEBI:6834
EC Number
206-217-9

SMALL SPILLS AND LEAKAGE: If you spill this chemical, you should dampen the solid spill material with water, then transfer the dampened material to a suitable container. Use absorbent paper dampened with water to pick up any remaining material. Seal your contaminated clothing and the absorbent paper in a vapor-tight plastic bag for eventual disposal. Wash all contaminated surfaces with a strong soap and water solution. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned.

Isolation and EvacuationExcerpt from ERG Guide 151 [Substances - Toxic (Non-Combustible)]:
Personal Protective Equipment (PPE) · 1 item

RECOMMENDED RESPIRATOR: Where the neat test chemical is weighed and diluted, wear a NIOSH-approved half face respirator equipped with a combination filter cartridge, i.e. organic vapor/acid gas/HEPA (specific for organic vapors, HCl, acid gas, SO2 and a high efficiency particulate filter). (NTP, 1992)

Toxicology

Treatment · 1 item

Establish an airway and ensure oxygenation and ventilation. Resuscitative measures should be initiated promptly. For hypotension, intravenous fluids should be administered and the patient's legs raised. If desirable increase in blood pressure is not obtained, vasopressor and/or inotropic drugs may be used as dictated by the clinical situation. For convulsions, diazepam intravenously and phenytoin may be required. If the seizures are refractory to diazepam and phenytoin, general anesthesia and paralysis with a neuromuscular blocking agent may be necessary. Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc. Absorption of drugs from the gastrointestinal tract may be decreased by giving activated charcoal, which, in many cases, is more effective than emesis or lavage; consider charcoal instead of or in addition to gastric emptying. Repeated doses of charcoal over time may hasten elimination of some drugs that have been absorbed. Safeguard the patient's airway when employing gastric emptying or charcoal. (L1712)

Health EffectsThey cause slurred speech, disorientation and "drunken" behavior. They are physically and psychologically addictive.
Exposure RoutesParenteral (intramuscular, intravenous). The absolute bioavailability following rectal administration of methohexital is 17%.
Toxicity Summary · 1 item

Methohexital binds at a distinct binding site associated with a Cl<sup>-</sup> ionopore at the GABA<sub>A</sub> receptor, increasing the duration of time for which the Cl<sup>-</sup> ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.

Signs and Symptoms · 1 item

The onset of toxicity following an overdose of intravenously administered methohexital will be within seconds of the infusion. If methohexital is administered rectally or is ingested, the onset of toxicity may be delayed. The manifestations of an ultrashort-acting barbiturate in overdose include central nervous system depression, respiratory depression, hypotension, loss of peripheral vascular resistance, and muscular hyperactivity ranging from twitching to convulsive-like movements. Other findings may include convulsions and allergic reactions.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Methohexital sodium

Ambiguous-DILI-concern

3

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Safety data

ridadr
3249
hazard_class
6.1(b)
packing_group
III

UsesAnesthetic (intravenous).

General DescriptionWhite powder.

Upstream & downstream products

Upstream raw materials

MagnesiumDiethyl malonateBromoethanePhosphorus tribromideAcetaldehydeAllyl bromideSodiumEthanolMethylurea

Additional notes

DefinitionChEBI: The sodium salt of methohexital.